Curaleaf, Inc. (CSE: CURA) has announced this morning that the company is planning to launch their own line of domestically grown premium hemp-derived Cannabidiol (CBD) products called, Curaleaf Hemp. Their new product line will be distributed throughout the United States.
Currently, Curaleaf operates 33 cannabis dispensaries, 12 cultivation sites and 10 processing facilities in across 12 different states. They have focused their business model on setting up their operations in highly populated areas in states like Florida, Massachusetts, New Jersey and New York.
The new Curaleaf Hemp product line, which is available for purchase today, features:
- Drops: CBD oil in droplet forms mixed with natural essential oils; available in Lemon Bergamot, Lavender Sweet Orange, Ginger Clove Cinnamon, Vanilla Ylang Ylang and Jasmine Wintergreen
- Lotions: Topical cream for everyday pain relief; available in Lemongrass and Menthol
- Soft-Gel Capsules: Convenient capsules perfect for daily use
- Disposable Vape Pens: On-the-go vape pens; available in Lemon Bergamot, Lavender Sweet Orange, Ginger Clove Cinnamon, Vanilla Ylang Ylang and Jasmine Wintergreen
Their team of product developers have focuses on offering consumers all natural, non-toxic, CBD products that are manufacturing with the highest standards from industrial hemp grown in the U.S.
Joe Lusardi, President and Chief Executive Officer of Curaleaf, stated “Expanding our presence within the industry and entering the consumer goods marketplace with Curaleaf Hemp is an exciting step for the company. Patients already trust and rely on Curaleaf for the highest-quality medical cannabis products and we have taken that same care with the development of Curaleaf Hemp. Supporting overall wellness, Curaleaf Hemp is a consistent and reliable line of hemp-based CBD products that consumers can trust. We expect this to become a significant economic contributor to our business in the years to come.”
You may be interested
Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio OregonEditor - November 27, 2018
Vancouver, BC -- (November 27, 2018) -- GLOBAL HEMP GROUP INC. (“GHG” or the “Company”) (CSE: GHG / OTC: GBHPF / FRANKFURT: GHG) and its joint venture…
Wayland Group Enters UK Cannabis Market with Theros Pharma AcquisitionEditor - November 26, 2018
Wayland Group (CSE:WAYL) (OTCQB:MRRCF) has announced this morning that their company has entered into an agreement to acquire 51% of UK company Theros Pharma Ltd. The Wayland Group…
GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical TrialsEditor - November 26, 2018
GW Pharmaceuticals (Nasdaq: GWPH) has announced this morning that their company has completed a double-blind, placebo-controlled Phase 3 clinical trial for its Cannabidiol (CBD) derived product EPIDIOLEX®.…